RHINOCORT Drug Patent Profile
✉ Email this page to a colleague
When do Rhinocort patents expire, and what generic alternatives are available?
Rhinocort is a drug marketed by Astrazeneca and J And J Consumer Inc and is included in two NDAs.
The generic ingredient in RHINOCORT is budesonide. There are twenty-two drug master file entries for this compound. Forty-three suppliers are listed for this compound. Additional details are available on the budesonide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rhinocort
A generic version of RHINOCORT was approved as budesonide by TEVA PHARMS on November 18th, 2008.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RHINOCORT?
- What are the global sales for RHINOCORT?
- What is Average Wholesale Price for RHINOCORT?
Summary for RHINOCORT
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Clinical Trials: | 13 |
Patent Applications: | 6,337 |
DailyMed Link: | RHINOCORT at DailyMed |
Recent Clinical Trials for RHINOCORT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, Los Angeles | Phase 4 |
Medstar Health Research Institute | Phase 4 |
University of Wisconsin, Madison | Phase 4 |
US Patents and Regulatory Information for RHINOCORT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | RHINOCORT | budesonide | AEROSOL, METERED;NASAL | 020233-001 | Feb 14, 1994 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
J And J Consumer Inc | RHINOCORT ALLERGY | budesonide | SPRAY, METERED;NASAL | 020746-003 | Mar 23, 2015 | OTC | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for RHINOCORT
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Dr. Falk Pharma GmbH | Jorveza | budesonide | EMEA/H/C/004655 Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). |
Authorised | no | no | yes | 2018-01-08 | |
Stada Arzneimittel AG | Kinpeygo | budesonide | EMEA/H/C/005653 Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram. |
Authorised | no | no | yes | 2022-07-15 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |